Private Companies Are Shanghai Labway Clinical Laboratory Co., Ltd.'s (SZSE:301060) Biggest Owners and Were Hit After Market Cap Dropped CN¥1.3b
A look at the shareholders of Shanghai Labway Clinical Laboratory Co., Ltd. (SZSE:301060) can tell us which group is most powerful. The group holding the most number of shares in the company, around
Shanghai Labway Plans $96 Million Share Sale to Fund New Laboratories
06:28 AM EDT, 09/05/2022 (MT Newswires) -- Shanghai Labway Clinical Laboratory (SHE:301060) is looking to raise 664.5 million yuan ($96 million) in a private placement of shares to fund the constructi
Do Institutions Own Shanghai Labway Clinical Laboratory Co., Ltd. (SZSE:301060) Shares?
The big shareholder groups in Shanghai Labway Clinical Laboratory Co., Ltd. (SZSE:301060) have power over the company. Institutions often own shares in more established companies, while it's not unus
We Think That There Are Issues Underlying Shanghai Labway Clinical Laboratory's (SZSE:301060) Earnings
Shanghai Labway Clinical Laboratory Co., Ltd. (SZSE:301060) just reported some strong earnings, and the market rewarded them with a positive share price move. We did some analysis and think that inv
Is Shanghai Labway Clinical Laboratory Co., Ltd.'s (SZSE:301060) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Shanghai Labway Clinical Laboratory's (SZSE:301060) stock is up by a considerable 24% over the past three months. Since the market usually pay for a company's long-term fundamentals, we decided to
Shanghai Labway Clinical Laboratory to Free Up 2.6 Million Shares as IPO Lock-Up Ends; Shares Rally 20%
11:51 PM EST, 03/10/2022 (MT Newswires) -- Shanghai Labway Clinical Laboratory (SHE:301060) will lift the restrictions on 2.6 million shares representing 0.66% of its share capital, the Chinese medica
Lanwei Medical: some cash management products earn 620000 yuan from maturity redemption.
Lanwei Medical (301060) announced that recently, the company used some of the temporarily idle raised funds of 80 million yuan to buy the "2021 structured deposit pegged exchange rate customized product 94" purchased by the Shanghai Branch of China Everbright Bank Co., Ltd. has expired. At present, the company has redeemed the principal of 80 million yuan and made a profit of 620000.00 yuan. The above principal and income have been returned to the company's fund-raising account.
Is there an attack of new strains from overseas? The demand for testing preparation surged and the price soared. COVID-19 testing concept stock broke out.
The leakage of the house was rained all night, and against the backdrop of the tense global epidemic situation, there was suddenly bad news. A newly discovered coronavirus strain has made the global epidemic situation more tense once again. On January 9, according to Israeli media reports, researchers at the University of Cyprus suspected of finding a new recombinant crown virus strain of Delta and Omicron locally, whose gene was closer to that of Delta virus, but had a large number of unique variants of Omicron virus. Therefore, the strain was named "Deltacron" by the researchers. It is reported that 25 people have been found to have been infected with the new strain, although its gene sequence is similar to that of Germany.
Real estate finance jointly launched a comprehensive rebound in A-shares. Changyang Prev rose nearly 1% and regained 3600 points.
On December 21, the three major A-share indices collectively opened low, and then the trend differentiated, the Prev maintained a slight rise in the red market, the gem index rose slightly, and the real estate stocks continued yesterday's hot mood to set off a stoppage. And led to prefabricated construction, building materials, household light industry and other real estate industry chain collectively rushed higher, scenic spots and tourism, meta-universe concept strengthened, agricultural cultivation, salt lake lithium, liquor and other plates weakened. In the afternoon, the Sanda Index rebounded across the board, the gem Index turned red, the Prev Index rose, the Shenzhen Composite Index continued to rise, real estate stocks rose by the daily limit, major financial sectors such as banks and securities continued to be active, education, power and other sectors warmed up, the automobile industry chain,
The latest announcement of Lanwei Medical: elect Zeng Weixiong as Chairman and appoint Gao Wenjun as Chief Financial Officer
Lanwei Medical announced that Zeng Weixiong was elected chairman of the third board of directors of the company, Zeng Weixiong was appointed general manager of the company, Mao Zhisen was appointed deputy general manager of the company, and Gao Wenjun was appointed financial director and secretary of the board of directors. Yang Jingjing was appointed as the company's securities representative. The chairman of the company is Zeng Weixiong. Mr. Zeng Weixiong: born in July 1968, Chinese nationality, no permanent residence abroad, master's degree, once worked as an inspection technician in the second affiliated Hospital of Hubei Medical College (now Zhongnan Hospital of Wuhan University). Successively founded Wuhan Lanqiao Medical equipment Co., Ltd., Hunan Shujia Scientific instrument Co., Ltd., Shanghai Shue Jia Bioengineering Co., Ltd.